Jupiter Neurosciences, Inc. (NASDAQ: JUNS)

Sector: Healthcare Industry: Biotechnology CIK: 0001679628
Market Cap 17.73 Mn
P/B 308.75
P/E -2.33
P/S 0.00
ROIC (Qtr) -853.66
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 180,393.00
Debt/Equity (Qtr) 3.14
Add ratio to table...

About

Investment thesis

Bull case

  • Healthy cash reserves of 723797 provide 4.01x coverage of short-term debt 180393, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 2.58M provides 14.28x coverage of total debt 180393, indicating robust asset backing and low credit risk.
  • Robust R&D investment of 2.24M at 0.42x of SG&A 5.31M demonstrates strong commitment to innovation and future growth.
  • Operating cash flow of (6.74M) exceeds working capital of (886484) by 7.60x, showing strong operational efficiency.
  • Cash position of 723797 fully covers payables of 478352 by 1.51x, showing strong vendor relationship management.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 2.24M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (6.74M) shows concerning coverage of stock compensation expenses of 2.97M, with a -2.27 ratio indicating potential earnings quality issues.
  • Debt issuance of (2.36M) significantly exceeds working capital of (886484), which is 2.66x, indicating potentially unsustainable leverage for operational funding.
  • Operating cash flow of (6.74M) is outpaced by equity issuance of 9.83M (-0.69 ratio), indicating concerning reliance on equity markets for funding operations.
  • Tangible assets of 2.58M provide limited backing for working capital of (886484), which is -2.91x, suggesting increased operational risk in market downturns.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 6.23 11.06
EV to Cash from Ops. EV/CFO -2.38 26.32
EV to Debt EV to Debt 88.93 762.61
EV to EBIT EV/EBIT -2.12 -13.49
EV to EBITDA EV/EBITDA -2.12 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -2.38 25.66
EV to Market Cap EV to Market Cap 0.90 203.37
EV to Revenue EV to Revenue 0.00 156.31
Price to Book Value [P/B] P/B 308.75 20.59
Price to Earnings [P/E] P/E -2.33 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) -221.79 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 285,985.77 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -617.70 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -250.41 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -617.70 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -466.28 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) -380.00 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -1,691.23 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 0.00 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 0.29 3.92
Current Ratio Curr Ratio (Qtr) 0.65 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 3.14 0.48
Interest Cover Ratio Int Coverage (Qtr) -221.79 956.66
Times Interest Earned Times Interest Earned (Qtr) -221.79 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 0.00 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) 0.00 -18,246.34
EBT Margin % EBT Margin % (Qtr) 0.00 -19,108.08
Gross Margin % Gross Margin % (Qtr) 0.00 -10.30
Net Profit Margin % Net Margin % (Qtr) 0.00 -19,056.96